DrugPatentWatch Database Preview

Upjohn Company Profile

« Back to Dashboard

What is the competitive landscape for UPJOHN, and when can generic versions of UPJOHN drugs launch?

UPJOHN has twenty-five approved drugs.

There is one US patent protecting UPJOHN drugs.

There are forty-nine patent family members on UPJOHN drugs in forty-six countries and forty-seven supplementary protection certificates in eleven countries.

Summary for Upjohn

International Patents:	49
US Patents:	1
Tradenames:	20
Ingredients:	16
NDAs:	25

Drugs and US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-001	Nov 2, 1990	AB	RX	Yes	Yes
Upjohn	NITROSTAT	nitroglycerin	TABLET;SUBLINGUAL	021134-002	May 1, 2000	AB	RX	Yes	No
Upjohn	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-005	Mar 6, 1996	AB	RX	Yes	No
Upjohn	REVATIO	sildenafil citrate	SOLUTION;INTRAVENOUS	022473-001	Nov 18, 2009	AP	RX	Yes	Yes
Upjohn	NEURONTIN	gabapentin	TABLET;ORAL	020882-002	Oct 9, 1998	AB	RX	Yes	Yes
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-004	Oct 20, 1997	AB	RX	Yes	Yes

Expired US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-001	Oct 20, 1997	6,274,171*PED
Upjohn	NITROSTAT	nitroglycerin	TABLET;SUBLINGUAL	021134-001	May 1, 2000	6,500,456
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-001	Dec 22, 2000	6,911,217*PED
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	4,599,353
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-002	Approved Prior to Jan 1, 1982	3,980,789
Upjohn	NITROSTAT	nitroglycerin	TABLET;SUBLINGUAL	021134-002	May 1, 2000	6,500,456

Paragraph IV (Patent) Challenges for UPJOHN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsules	2 mg and 4 mg		2007-07-30
	Capsules	20 mg, 40 mg, 60 mg and 80 mg		2005-02-07
	Tablets	20 mg and 40 mg		2010-03-29
	Tablets	100 mg		2004-10-25
	Sublingual Tablets	0.6 mg		2011-12-29
	Extended-release Tablets	37.5 mg, 75 mg and 150 mg		2007-05-03
	Tablets	150 mg and 200 mg		2005-11-09
	Tablets	25 mg and 50 mg		2004-11-19
	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg		2005-10-19

International Patents for Upjohn Drugs

Country	Patent Number	Estimated Expiration
Ukraine	75138
Ecuador	SP034853
Norway	20035200
Brazil	0209973
Denmark	1395242
China	100346779

Supplementary Protection Certificates for Upjohn Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	92545	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0364417	9690031-1	Sweden		PRODUCT NAME: LATANOPROST
0325571	SPC/GB98/027	United Kingdom		PRODUCT NAME: TOLTERODINE OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: SE 13475 19970905; SE 13476 19970905; UK 00032/0222 19980203; UK 00032/0223 19980203
0473687	SPC/GB98/030	United Kingdom		PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0473687	3/1999	Austria		PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Upjohn